[Skip to Navigation]
April 26, 2021

Incorporating Adult Evidence Into Pediatric Research and Practice: Bayesian Designs to Expedite Obtaining Child-Specific Evidence

Author Affiliations
  • 1Department of Pediatrics, University of British Columbia, Vancouver, British Columbia, Canada
  • 2Department of Pediatrics, McGill University, Montreal, Quebec, Canada
  • 3Berry Associates, Austin, Texas
JAMA. 2021;325(19):1937-1938. doi:10.1001/jama.2020.25007

The need for child-specific knowledge acquisition through high-quality clinical trials is clear. Due to differences in drug metabolism or pathophysiology, children may respond differently than adults to various therapies, even when used to treat the same disease.1 This is reflected in the stated need from regulators, such as the US Food and Drug Administration (FDA), for child-specific knowledge generation. As the COVID-19 pandemic has demonstrated, it has been difficult to generate child-specific data in a timeframe that is scientifically robust and clinically actionable.

Limit 200 characters
Limit 25 characters
Conflicts of Interest Disclosure

Identify all potential conflicts of interest that might be relevant to your comment.

Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.

Err on the side of full disclosure.

If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.

Not all submitted comments are published. Please see our commenting policy for details.

Limit 140 characters
Limit 3600 characters or approximately 600 words